Singapore-listed iX Biopharma reported successful Phase IIa and IIb clinical trials for pain relief lead candidate Wafermine, setting the stage for moving to Phase III, according to the Business Times. The company listed on SGX Catalist sponsor-supervised board in July, after an initial public offering of 65.5 million new shares at S$0.46 each to raise S$27.6 million, according to its website. The Phase II work was conducted in the United States and involved 200 patients undergoing dental surgery, the Business Times said. According to the newspaper, the company now plans a limited study for multiple-dosing with Wafermine before embarking on Phase III next year. Release